Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012

Donal McLornan, Adam J. Mead, Graham Jackson, Claire Harrison

Research output: Contribution to journalLiterature reviewpeer-review

44 Citations (Scopus)

Abstract

Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of conditioning regimen. This review summarizes key findings from published data concerning AHSCT in MF and attempts to provide a state of the art approach to MF-AHSCT in 2012. In addition, we postulate on how the era of JAK inhibition might impact on transplantation for MF.

Original languageEnglish
Pages (from-to)413-425
Number of pages13
JournalBritish Journal of Haematology
Volume157
Issue number4
DOIs
Publication statusPublished - May 2012

Keywords

  • myelofibrosis
  • stem cell transplant
  • splenectomy
  • JAK inhibitors
  • VERSUS-HOST-DISEASE
  • INTERNATIONAL WORKING GROUP
  • AGNOGENIC MYELOID METAPLASIA
  • CORD BLOOD TRANSPLANTATION
  • PROGNOSTIC SCORING SYSTEM
  • DONOR-LYMPHOCYTE INFUSION
  • REAL-TIME PCR
  • POLYCYTHEMIA-VERA
  • ESSENTIAL THROMBOCYTHEMIA
  • IDIOPATHIC MYELOFIBROSIS

Fingerprint

Dive into the research topics of 'Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012'. Together they form a unique fingerprint.

Cite this